<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00591383</url>
  </required_header>
  <id_info>
    <org_study_id>IBL1004</org_study_id>
    <nct_id>NCT00591383</nct_id>
  </id_info>
  <brief_title>Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors</brief_title>
  <official_title>Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ziopharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ziopharm</source>
  <brief_summary>
    <textblock>
      Single arm, open label, Phase I, dose-escalation study of indibulin in combination with&#xD;
      erlotinib in subjects with advanced histologically confirmed, solid tumors for which no&#xD;
      standard therapy exists and for whom treatment with erlotinib is considered medically&#xD;
      acceptable.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>toxicities</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once Maximum Tolerated Dose (MTD) is determined an expanded cohort will be enrolled to evaluate efficacy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indibulin</intervention_name>
    <description>indibulin, dose escalation, 200 mg - 600 mg. Taken twice every day.</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>ZIO-301</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>erlotinib taken at 150 mg every morning with food.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects with advanced, histologically confirmed solid tumors for which no standard&#xD;
             therapy exists and for whom treatment with erlotinib is considered medically&#xD;
             acceptable.&#xD;
&#xD;
          2. ≥18 years of age&#xD;
&#xD;
          3. ECOG performance score ≤2&#xD;
&#xD;
          4. Eligible subjects MUST have at least one measurable lesion as defined by RECIST&#xD;
             guidelines. Measurable lesions MUST NOT have been in a previously irradiated field or&#xD;
             injected with biological agents.&#xD;
&#xD;
          5. Life-expectancy ≥12 weeks&#xD;
&#xD;
          6. No more than 2 prior chemotherapy regimens for metastatic disease&#xD;
&#xD;
          7. Adequate bone marrow, liver and renal function as assessed by the following laboratory&#xD;
             requirements to be conducted &lt;2 weeks prior to Study Day 1:&#xD;
&#xD;
               -  Creatinine ≤1.5×upper limit of normal (ULN) OR a calculated creatinine clearance&#xD;
                  ≥50 cc/min&#xD;
&#xD;
               -  Total bilirubin ≤1.5×ULN&#xD;
&#xD;
               -  Alanine transaminase (ALT) and aspartate transaminase (AST) ≤2.5×ULN&#xD;
&#xD;
               -  White blood cell count ≥3.0×109/L&#xD;
&#xD;
               -  Absolute Neutrophil Count (ANC) ≥1.5×109/L&#xD;
&#xD;
               -  Platelets ≥100×109/L&#xD;
&#xD;
               -  Hemoglobin ≥10 g/dL&#xD;
&#xD;
          8. Written informed consent in compliance with ZIOPHARM policies and the Human&#xD;
             Investigation Review Committee with jurisdiction over the site.&#xD;
&#xD;
          9. Each man and woman of childbearing potential must agree to use a reliable method of&#xD;
             contraception during the study and for 3 months following the last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. New York Heart Association (NYHA) functional class ≥3 or myocardial infarction within&#xD;
             6 months (see Appendix 5)&#xD;
&#xD;
          2. Uncontrolled cardiac arrhythmia other than asymptomatic atrial fibrillation&#xD;
&#xD;
          3. Subjects cannot be receiving cytochrome P450-inducing anticonvulsants (EIAEDs: eg,&#xD;
             phenytoin, carbamazepine, phenobarbital, primidone, oxcarbezine)&#xD;
&#xD;
          4. Subjects may not be taking CYP3A4 inducers (rifampicin)&#xD;
&#xD;
          5. Subjects must not have any evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
          6. Subjects with international normalized ration (INR) &gt;1.5 are excluded, unless the&#xD;
             subject is on full dose warfarin&#xD;
&#xD;
          7. Subjects on full-dose anticoagulants (eg, warfarin) are eligible provided that both of&#xD;
             the following criteria are met:&#xD;
&#xD;
               -  The subject has an in-range INR (usually between 2 and 3) on a stable dose of&#xD;
                  oral anticoagulant or on a stable dose of low molecular weight heparin&#xD;
&#xD;
               -  The subject has no active bleeding or pathological condition that carries a high&#xD;
                  risk of bleeding (eg, tumor involving major vessels or known varices.&#xD;
&#xD;
          8. Subjects on prophylactic anticoagulation (ie, low-dose warfarin) are eligible provided&#xD;
             their coagulation parameter levels are as follows: prothrombin time (INR of&#xD;
             prothrombin time) &lt;1.1×institutional ULN&#xD;
&#xD;
          9. Pregnancy and/or lactation&#xD;
&#xD;
         10. Uncontrolled systemic infection (documented with microbiological studies)&#xD;
&#xD;
         11. Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of study&#xD;
             entry. Mitomycin C or nitrosureas should not be given within 6 weeks of study entry.&#xD;
&#xD;
         12. Prior treatment with EGFR inhibitors&#xD;
&#xD;
         13. Radiotherapy during the study or within 3 weeks of study entry&#xD;
&#xD;
         14. Surgery within 4 weeks of start of study drug excluding tumor biopsy for&#xD;
             pharmacodynamic parameters&#xD;
&#xD;
         15. Investigational drug therapy outside of this trial during or within 4 weeks of study&#xD;
             entry&#xD;
&#xD;
         16. History of an invasive second primary malignancy diagnosed within the previous 3 years&#xD;
             except for Stage I endometrial/cervical carcinoma or prostate carcinoma treated&#xD;
             surgically, and non-melanoma skin cancer&#xD;
&#xD;
         17. Substance abuse, medical, psychological or social conditions that may interfere with&#xD;
             the subject's participation in the study or evaluation of the study results&#xD;
&#xD;
         18. Any condition that is unstable or could jeopardize the safety of the subject and&#xD;
             his/her compliance with the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Lewis, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ziopharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>December 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2008</study_first_posted>
  <last_update_submitted>July 18, 2012</last_update_submitted>
  <last_update_submitted_qc>July 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Indibulin</keyword>
  <keyword>Erlotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

